Fig. 1From: Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated – NIVACOR trial (GOIRC-03-2018)Study Design. Primary Endpoint: Overall Response Rate (ORR) per investigator assessment (RECIST v1.1). *SD: stable disease, RP: partial response, RC: complete responseBack to article page